Form 8-K - Current report:
SEC Accession No. 0001404644-25-000053
Filing Date
2025-06-12
Accepted
2025-06-12 16:20:40
Documents
14
Period of Report
2025-06-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngne-20250612.htm   iXBRL 8-K 49707
2 EX-10.1 ngne2023equityincentivepla.htm EX-10.1 149752
3 EX-10.2 a2023esppasamendedjune2025.htm EX-10.2 103513
  Complete submission text file 0001404644-25-000053.txt   473139

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20250612.xsd EX-101.SCH 1788
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20250612_lab.xml EX-101.LAB 22548
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20250612_pre.xml EX-101.PRE 13050
16 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20250612_htm.xml XML 2802
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 251042962
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)